Exchange: NASDAQ·Updated 07:27 AM EDT

BIIB News

News
all
press releases
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
Zacks
More News
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September...
Business Wire
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...
Business Wire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September...
Business Wire
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Zacks
Biogen: LEQEMBI IQLIK Autoinjector Available In U.S. For Early Alzheimer's
(RTTNews) - Eisai Co. (4523.T, EII.SG) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection - LEQEMBI IQLIK - is now available in the U.S. for initiation therapy for early Alzheimer's disease in adults with mild cognitive impairment or mild dementia...
Nasdaq News: Markets
LEQEMBI IQLIK(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease LEQEMBI IQLIK(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., Aug. 24...
PR Newswire

Advertisement|Remove ads.